Rocket Lab shares are down 55% from their May high and trade around $67.50, while the article argues the stock remains overvalued. The company’s proposed $8B acquisition of Iridium (with $871M revenue) is framed as a push to compete directly with SpaceX and accelerate commercial Neutron flights, potentially accelerating vertical integration and Starlink-like capabilities. Despite $680M trailing-12-month revenue (up 1,000% over five years), the stock’s P/S multiple of 55 is cited as unsustainably high even if revenues grow 10x, implying dilution risk; the recommendation is to wait for a further drop.
The market is pricing RKLB like a scarce platform winner, but the business still behaves like a capital-intensive engineering story, not a cash compounder. At this valuation, execution misses matter asymmetrically: a few quarters of launch delay, integration friction, or financing dilution can compress the multiple faster than incremental revenue can expand it.
The strategic logic of owning spectrum and satcom assets is real, but that optionality is being valued as if it arrives with near-term cash flow. In practice, the more likely second-order effect is balance-sheet drag: management attention, leverage capacity, and equity issuance risk rise just as the company needs maximum flexibility to prove Neutron reliability. That tends to favor better-capitalized incumbents and defense/aerospace names with established FCF over the next 6-18 months.
The contrarian bull case is that scarcity can stay expensive longer than skeptics expect if the deal clears and the launch roadmap stays on schedule. But the falsifier is straightforward: any slip in deal financing, any setback in commercial flight cadence, or any margin dilution in guidance should trigger another derating. Near term, the setup is a catalyst-driven valuation test; structurally, it is a patience trade, not a cheap-growth entry point.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
